23:44 , May 23, 2019 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
20:57 , May 22, 2019 |  BC Extra  |  Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
14:42 , May 20, 2019 |  BC Extra  |  Financial News

May 20 Financial Quick Takes: Schrödinger tops off E round; plus Mabpharm IPO update, DNA Script, ADMA Biologics, Storm

Schrödinger brings E round to $110M  Computational physics company Schrödinger LLC (New York, N.Y.) closed the second tranche of its total $110 million series E round to support development of its technology platform and expand...
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
23:45 , May 9, 2019 |  BC Extra  |  Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials  Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
21:58 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate. In a Nature paper published Wednesday, Salk's Tony...
22:49 , Apr 16, 2019 |  BC Extra  |  Company News

WuXi Biologics to supply CMC and commercial manufacturing for I-Mab

WuXi Biologics expanded its partnership with I-Mab to include biologics process development and clinical and commercial manufacturing of at least six undisclosed programs. WuXi Biologics Inc. (HKSE:2269) will provide CMC services for at least five...